Related Experiment Video
Updated: Sep 2, 2025
12:09
Protocol for Recombinant RBD-based SARS Vaccines: Protein Preparation, Animal Vaccination and Neutralization Detection
Published on: May 2, 2011
42.9K
Communicating about COVID-19 vaccine development and safety
Alistair Thorpe1, Angela Fagerlin1,2, Jorie Butler1,2,3
1Spencer Fox Eccles School of Medicine at University of Utah, Salt Lake City, UT, United States of America.
Plos One
|August 5, 2022
Summary
Messages addressing COVID-19 vaccine risks and development timelines did not increase vaccination intentions in a recent study. Further research is needed to effectively combat vaccine hesitancy and refusal.
Area of Science:
- Public Health
- Vaccinology
- Behavioral Science
Background:
- COVID-19 vaccine hesitancy is driven by concerns over vaccine risks versus disease risks.
- Perceived rushed vaccine development and lack of rigor also contribute to vaccine refusal.
Purpose of the Study:
- To test if messages addressing vaccine risk and development concerns can increase COVID-19 vaccination intentions.
- To evaluate the impact of risk comparison and development timeline messages on vaccine uptake.
Main Methods:
- An online survey with US Veterans and non-Veterans (n=1075) was conducted.
- Participants were randomly assigned to a control group or to read one of two messages: a risk comparison fact-box or a vaccine development timeline.
Main Results:
- Most respondents (60%) desired a COVID-19 vaccine, but 17% were hesitant and 23% refused.
- Neither the risk comparison nor the timeline message significantly improved vaccination intentions or reduced waiting times compared to the control group.
Conclusions:
- The tested messages did not impact vaccine intentions, indicating a need for different communication strategies.
- Further research is required to identify effective methods for addressing vaccine risk and development concerns to promote vaccine uptake.
More Related Videos
Related Concept Videos
01:19Pharmacovigilance
974
Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
974
01:28Preclinical Development: Overview
4.8K
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
4.8K
01:51Vaccinations
45.2K
Overview
45.2K
01:11Clinical Trials: Overview
3.3K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
3.3K
01:30Cancer Vaccines
500
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
500
01:22Development of Immunocompetence
440
The initiation of cell-mediated immunity can be observed as early as the third month of fetal growth, with active antibody-mediated immunity following approximately one month later.
The initial cells that migrate from the fetal thymus settle within the skin and epithelial tissues lining the mouth, digestive tract, and in females, the uterus and vagina. These cells, including skin-based dendritic cells, serve as antigen-presenting cells, playing a key role in T cell activation.
Subsequent T...
The initial cells that migrate from the fetal thymus settle within the skin and epithelial tissues lining the mouth, digestive tract, and in females, the uterus and vagina. These cells, including skin-based dendritic cells, serve as antigen-presenting cells, playing a key role in T cell activation.
Subsequent T...
440